Shares of PTC Therapeutics (PTCT) initially plunged more than 20% in after-hours trading Thursday but later rose 4%, after the company said it would still submit for approval its muscular-dystrophy drug that failed a late-stage trial. PTC said patients with Duchenne muscular dystrophy (DMD) who were given its drug Translarna for 48 weeks did not show a statistically significant improvement in distance traveled over the six-minute walk test. The
Biotech Sarepta Therapeutics (SRPT) revealed more data from its latest trial of muscular-dystrophy drug eteplirsen Thursday morning, sending the stock up sharply in early trading. Sarepta said that after three years on eteplirsen, the subjects of its phase-two study of Duchenne muscular dystrophy (DMD) in a six-minute walk test showed an advantage of 151 meters compared with the control group. The control group here was somewhat non-standard,
Biotech Sarepta Therapeutics (SRPT) got an upgrade and a price target increase Wednesday, a day after it said the FDA had finally accepted its filing for muscular-dystrophy drug eteplirsen. Late Tuesday, Sarepta said the agency had granted eteplirsen priority review and set its deadline for making an approval decision at Feb. 26. The drug treats cases of Duchenne muscular dystrophy (DMD) associated with a genetic mutation of exon 51, which